---
title: "Neoadjuvant Gemcitabine plus S-1 for Resectable PDAC: Propensity-Matched Outcomes"
id: "pubmed-42674690"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42674690"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42674690/"
doi: "10.21873/anticanres.18364"
published_at: "2026-09-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Neoadjuvant Gemcitabine plus S-1 for Resectable PDAC: Propensity-Matched Outcomes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42674690
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42674690/)
- **DOI:** [10.21873/anticanres.18364](https://doi.org/10.21873%2Fanticanres.18364)
- **Published At:** 2026-09-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This retrospective study evaluated the safety and efficacy of **neoadjuvant chemotherapy** with **gemcitabine plus S-1 (NAC-GS)** versus upfront surgery (UFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC). - The review included 117 patients treated between January 2017 and December 2024: 46 received NAC-GS and 71 underwent UFS. - Propensity score matching was applied among patients who underwent curative resection; 32 matched pairs were analyzed to adjust for baseline differences. - Resection rates were similar between the NAC-GS and UFS groups; NAC-GS did not reduce the ability to proceed to surgery. - Grade ≥3 adverse events occurred frequently in the NAC-GS group, but no patient became ineligible for surgery because of toxicity. - After matching, NAC-GS was associated with significantly longer **recurrence-free survival (RFS)** and **overall survival (OS)** compared with UFS: 5-year RFS 57.2% vs 26.0% and 5-year OS 60.2% vs 37.2%. - NAC-GS correlated with a lower rate of early recurrence compared with UFS. - Within the NAC-GS cohort, a **relative dose intensity (RDI)** below 70% tended to be associated with poorer survival, suggesting adequate dosing may be important for benefit. - The study concludes NAC-GS was feasible in real-world practice and linked to improved long-term outcomes and reduced early recurrence; maintaining adequate RDI may maximize therapeutic effect. - Details on certain items such as exact toxicity breakdowns, definitions of early recurrence, and additional subgroup analyses were not fully reported in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42674690/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674690%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42674690/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42674690/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42674690/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42674690/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42674690/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674690%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674690%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42674690/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674690/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674690/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42674690/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674690/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42674690/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42674690/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42674690/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42674690/#substances) Title & authors Abstract MeSH terms Substances Anticancer Res Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Res%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Res%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) . 2026 Sep;46(9):5193-5204. doi: 10.21873/anticanres.18364. # Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study [Takashi Kishi](https://pubmed.ncbi.nlm.nih.gov/?term=Kishi+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-2 "Department of Surgery, Hamada Medical Center, Shimane, Japan."), [Kosuke Nakamura](https://pubmed.ncbi.nlm.nih.gov/?term=Nakamura+K&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Takayuki Tanaka](https://pubmed.ncbi.nlm.nih.gov/?term=Tanaka+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Kazunari Ishitobi](https://pubmed.ncbi.nlm.nih.gov/?term=Ishitobi+K&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Shunsuke Kaji](https://pubmed.ncbi.nlm.nih.gov/?term=Kaji+S&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Takahito Taniura](https://pubmed.ncbi.nlm.nih.gov/?term=Taniura+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Takeshi Matsubara](https://pubmed.ncbi.nlm.nih.gov/?term=Matsubara+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Tetsu Yamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Masaaki Hidaka](https://pubmed.ncbi.nlm.nih.gov/?term=Hidaka+M&cauthor_id=42674690)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#full-view-affiliation-3 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan; mahidaka@med.shimane-u.ac.jp.") Affiliations Expand ### Affiliations * 1 Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan. * 2 Department of Surgery, Hamada Medical Center, Shimane, Japan. * 3 Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan; mahidaka@med.shimane-u.ac.jp. * PMID: **42674690** * DOI: [ 10.21873/anticanres.18364 ](https://doi.org/10.21873/anticanres.18364) Item in Clipboard # Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study Takashi Kishi et al. Anticancer Res. 2026 Sep. Show details Display options Display options Format Abstract PubMed PMID Anticancer Res Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Res%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Res%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) . 2026 Sep;46(9):5193-5204. doi: 10.21873/anticanres.18364. ### Authors [Takashi Kishi](https://pubmed.ncbi.nlm.nih.gov/?term=Kishi+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-2 "Department of Surgery, Hamada Medical Center, Shimane, Japan."), [Kosuke Nakamura](https://pubmed.ncbi.nlm.nih.gov/?term=Nakamura+K&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Takayuki Tanaka](https://pubmed.ncbi.nlm.nih.gov/?term=Tanaka+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Kazunari Ishitobi](https://pubmed.ncbi.nlm.nih.gov/?term=Ishitobi+K&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Shunsuke Kaji](https://pubmed.ncbi.nlm.nih.gov/?term=Kaji+S&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Takahito Taniura](https://pubmed.ncbi.nlm.nih.gov/?term=Taniura+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Takeshi Matsubara](https://pubmed.ncbi.nlm.nih.gov/?term=Matsubara+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Tetsu Yamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+T&cauthor_id=42674690)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-1 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan."), [Masaaki Hidaka](https://pubmed.ncbi.nlm.nih.gov/?term=Hidaka+M&cauthor_id=42674690)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42674690/#short-view-affiliation-3 "Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan; mahidaka@med.shimane-u.ac.jp.") ### Affiliations * 1 Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan. * 2 Department of Surgery, Hamada Medical Center, Shimane, Japan. * 3 Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan; mahidaka@med.shimane-u.ac.jp. * PMID: **42674690** * DOI: [ 10.21873/anticanres.18364 ](https://doi.org/10.21873/anticanres.18364) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Background/aim:** Neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC-GS) is recommended for patients with resectable pancreatic ductal adenocarcinoma (PDAC) in Japan. However, its real-world feasibility, the impact of treatment-related toxicity, and the influence of relative dose intensity (RDI) on outcomes remain unclear. This study evaluated the safety and efficacy of NAC-GS for resectable PDAC. **Patients and methods:** We retrospectively reviewed 117 patients with resectable PDAC who underwent treatment between January 2017 and December 2024. Outcomes were compared between patients treated with NAC-GS and those who underwent upfront surgery (UFS). Propensity score matching was performed among patients who underwent curative resection to adjust for baseline characteristics. Recurrence-free survival (RFS), overall survival (OS), recurrence patterns, adverse events, and the association between RDI and outcomes were analyzed. **Results:** The study included 46 patients in the NAC-GS group and 71 in the UFS group. Resection rates did not differ significantly between the groups. Although grade ≥3 adverse events occurred frequently in the NAC-GS group, no patient became ineligible for surgery because of treatment-related toxicity. After propensity score matching, 32 pairs were analyzed. The NAC-GS group had significantly longer RFS and OS than the UFS group. The 5-year RFS rates were 57.2% and 26.0%, respectively, and the 5-year OS rates were 60.2% and 37.2%, respectively. NAC-GS was also associated with a lower early recurrence rate. In the NAC-GS group, an RDI <70% tended to be associated with poorer survival. **Conclusion:** NAC-GS was feasible and was associated with improved long-term outcomes and reduced early recurrence in patients with resectable PDAC. Maintaining adequate RDI may be important for maximizing its therapeutic benefit. **Keywords:** Pancreatic ductal adenocarcinoma; gemcitabine plus S-1; neoadjuvant chemotherapy; propensity score matching; relative dose intensity; resectable pancreatic cancer. Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Antineoplastic Combined Chemotherapy Protocols* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Antineoplastic Combined Chemotherapy Protocols* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Carcinoma, Pancreatic Ductal* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Pancreatic+Ductal%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Pancreatic+Ductal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Carcinoma, Pancreatic Ductal* / mortality Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Pancreatic+Ductal%2Fmortality%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Pancreatic+Ductal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Carcinoma, Pancreatic Ductal* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Pancreatic+Ductal%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Pancreatic+Ductal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Carcinoma, Pancreatic Ductal* / surgery Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Pancreatic+Ductal%2Fsurgery%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Pancreatic+Ductal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Deoxycytidine* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Deoxycytidine%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Deoxycytidine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Deoxycytidine* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Deoxycytidine%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Deoxycytidine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Deoxycytidine* / analogs & derivatives Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Deoxycytidine%2Fanalogs+and+derivatives%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Deoxycytidine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Deoxycytidine* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Deoxycytidine%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Deoxycytidine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Drug Combinations Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Combinations%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Combinations) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Gemcitabine Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gemcitabine%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gemcitabine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674690/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.go
## Related Clinical Research

- [Correction Notice: Physician Management of Immunoglobulin in Canada — S1 File Update](https://medichelpline.com/clinical-feed/plos-one-0-correction-physician-management-of-immunoglobulin-in-canada-a-qualitative-study.md)
- [Short-Term Relaxation + Music Does Not Prevent Depression, Anxiety, or GI Symptoms in Military Rec](https://medichelpline.com/clinical-feed/pubmed-42763415.md) (DOI: 10.12659/MSM.953585)
- [Lactobacillus acidophilus Improves Hepatic and Microbial Dysregulation in MASLD and Diabetes](https://medichelpline.com/clinical-feed/pubmed-42760849.md) (DOI: 10.1080/19490976.2026.2734705)
- [Trump Announces GENEROUS Medicaid Drug-Discount Model; 40 States Reportedly Signed So Far](https://medichelpline.com/clinical-feed/stat-news-0-stat-trump-touts-pharma-deals-to-offer-cheaper-drugs-to-state-medicaid-programs.md)
- [Pharmalot job moves: IN8bio hires Oxana Polyakova as senior VP, R&D](https://medichelpline.com/clinical-feed/stat-news-1-stat-up-and-down-the-ladder-the-latest-comings-and-goings.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.